Glucosamine / Chondroitin

Evidence Fact Sheet

Glucosamine (commonly the sulfate or HCl salt, often paired with chondroitin) is an amino-sugar studied as a substrate precursor for cartilage glycosaminoglycan synthesis. Human evidence in knee osteoarthritis is large but mixed and form-dependent; EFSA rejected all EU joint-health claims. Typical research dose 1500 mg/day.

Also known as: Glucosamine Sulfate · Glucosamine HCl · Crystalline Glucosamine Sulfate (pCGS) · Chondroitin Sulfate · Glucosamine-Chondroitin Combination

Overview

Glucosamine is an amino-sugar (typically supplied as crystalline glucosamine sulfate or glucosamine HCl, frequently combined with chondroitin sulfate) studied as a substrate precursor for glycosaminoglycan and proteoglycan synthesis in articular cartilage, with proposed hexosamine-pathway and NF-kB/COX-2-related signaling effects described mechanistically. It is most researched for knee osteoarthritis symptom support, with the strongest signals reported for crystalline glucosamine sulfate at the typical research dose of 1500 mg/day (often with 1200 mg/day chondroitin); clinical onset in trials is slow. In the US it is a DSHEA dietary-supplement ingredient (structure/function claims only); EFSA rejected all Article 13 joint-health claims, while crystalline glucosamine sulfate is separately a prescription drug in several EU states. Most material is crustacean-derived, a hard allergen red line.

Mechanism of Action

Substrate precursor for glycosaminoglycan / proteoglycan synthesis in articular cartilage (research-described) · Hexosamine pathway flux modulation (mechanistic, proposed link to anti-inflammatory and low-carb-mimetic signaling) · NF-kB signaling inhibition (preclinical / mechanistic) · COX-2 expression and PGE2 down-regulation (preclinical / mechanistic) · Associated with lower circulating CRP in cohort data (observational, not causal)

Body systems: Musculoskeletal · Cardiovascular · Immune System · Digestive & Gut

Evidence-Based Benefits

Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Glucosamine / Chondroitin is not characterized as a treatment for any disease.

Knee Osteoarthritis Symptoms (Primary RCT)

Null / no benefit RCT supported

P=0.30glucosamine vs placebo · NS
+6.5 ptscombination · P=0.09
n=1,583NIH GAIT trial

In the large NIH-funded GAIT trial, glucosamine HCl (alone or combined with chondroitin) was not significantly better than placebo for the primary endpoint of a 20% reduction in knee pain. A benefit reached significance only in a pre-specified moderate-to-severe baseline-pain subgroup, which the authors framed as exploratory. This is a key honest negative for the HCl form.

Reported effect: Glucosamine HCl +3.9 points vs placebo (P=0.30, not significant); glucosamine + chondroitin +6.5 points (P=0.09); placebo response rate 60.1%; n=1,583

Source: PMID 16495392 · Clegg 2006 · N Engl J Med

Glucosamine + Chondroitin Combination (Meta-Analysis)

Meta-analysis supported

-12.04WOMAC total MD · p=0.02
8 RCTs3,793 participants

A meta-analysis of the glucosamine-plus-chondroitin combination found a statistically significant advantage over placebo on the total WOMAC score, but no significant effect on VAS pain across comparisons. The mixed picture (function/composite better, standalone pain not) illustrates why the evidence is considered heterogeneous rather than definitive.

Reported effect: Total WOMAC MD = -12.04 (95% CI -22.33 to -1.75; P=0.02); 8 RCTs, 3,793 participants (1,067 on combination); VAS: none of the comparisons showed significance

“Regarding the total Western Ontario and McMaster Universities Arthritis Index (WOMAC) score, compared with the placebo group, the combination group showed a statistically significant advantage [MD = - 12.04 (- 22.33 ~ - 1.75); P = 0.02] ... Regarding the VAS score, none of the comparisons showed significance.”

Source: PMID 35024906 · Meng 2023 · Arch Orthop Trauma Surg

Glucosamine Monotherapy for OA Pain (Meta-Analysis)

Null / no benefit Meta-analysis supported

clinicallyunimportant effect

A BJSM meta-analysis of 69 RCTs of dietary supplements for osteoarthritis concluded that widely used supplements such as glucosamine and chondroitin were either ineffective or showed small, arguably clinically unimportant treatment effects. The abstract characterized any glucosamine pain benefit as of unclear clinical importance rather than reporting a usable pooled number, so no effect size is extracted here. This is a central honest negative.

Effect size: this study reports the direction of the finding but does not state a specific numeric effect size, so none is given here rather than estimated.

“Some supplements with a limited number of studies and participants suggested large treatment effects, while widely used supplements such as glucosamine and chondroitin were either ineffective or showed small and arguably clinically unimportant treatment effects.”

Source: PMID 29018060 · Liu 2018 · Br J Sports Med

Form-Specific Effects: Glucosamine Sulfate vs Combination (SR/MA)

Meta-analysis supported

A 2024 systematic review and meta-analysis reported that glucosamine sulfate significantly reduced tibiofemoral joint-space narrowing, while the glucosamine-plus-chondroitin combination showed neither a reduction in pain intensity nor improvement in physical function. The abstract reports these findings qualitatively without pooled effect sizes, so no number is extracted. It underscores that benefit is form- and endpoint-dependent.

Effect size: this study reports the direction of the finding but does not state a specific numeric effect size, so none is given here rather than estimated.

“GS showed a significant reduction in tibiofemoral joint space narrowing ... the combination of GS and CS showed neither a reduction in pain intensity, nor any improvement in the physical function”

Source: PMID 38581640 · Rabade 2024 · Inflammopharmacology

Cartilage Structure / Joint-Space Width (GAIT Structural Arm)

Null / no benefit RCT supported

581 knees357 subjects analyzed

In the GAIT structural sub-study, no treatment group (including glucosamine) showed a statistically significant difference in mean joint-space-width loss over 2 years versus placebo, and none reached the predefined threshold for a clinically important structural difference. This is an honest negative for the disease-modifying / cartilage-preservation hypothesis in this trial.

Reported effect: No statistically significant difference in mean JSW loss in any treatment group vs placebo over 2 years; 357 subjects / 581 knees analyzed

“No statistically significant difference in mean JSW loss was observed in any treatment group compared with the placebo group.”

Source: PMID 18821708 · Sawitzke 2008 · Arthritis Rheum

Inflammatory-Marker (CRP) Modulation (RCT in Healthy Adults)

RCT supported

23% lowerserum CRP · p=0.048
n=18healthy overweight adults
IL-6 NSother markers unchanged

In a small crossover RCT of healthy overweight adults, glucosamine plus chondroitin lowered serum CRP by 23% versus placebo, with no significant change in IL-6, sTNF receptors, PGE2-metabolite, or F2-isoprostane. The signal is on an inflammatory biomarker in healthy people, not a clinical outcome, and the sample is small.

Reported effect: Serum CRP 23% lower after glucosamine and chondroitin vs placebo (P=0.048); n=18 healthy overweight adults; IL-6, sTNFR I/II, PGE2-M, F2-isoprostane not significantly different

“Serum CRP concentrations were 23% lower after glucosamine and chondroitin compared to placebo (P = 0.048).”

Source: PMID 25719429 · Navarro 2015 · PLoS One

All-Cause and Cardiovascular Mortality Association (Cohort — Observational)

Emerging / indexed

HR 0.85all-cause · 95% CI 0.82-0.89
HR 0.82CVD mortality · 95% CI 0.74-0.90
495,077UK Biobank participants

In the UK Biobank prospective cohort, regular glucosamine use was associated with lower all-cause mortality (HR 0.85) and cardiovascular mortality (HR 0.82). This is an observational association only, prone to healthy-user / selection bias, and must not be read as a causal or longevity claim — independent commentaries have specifically flagged selection bias in this literature.

Reported effect: All-cause mortality HR 0.85 (95% CI 0.82 to 0.89); CVD mortality HR 0.82 (95% CI 0.74 to 0.90); 495,077 participants

“the HRs associated with glucosamine use were 0.85 (95% CI 0.82 to 0.89) ... [for cardiovascular disease mortality] 0.82 (95% CI 0.74 to 0.90)”

Source: PMID 32253185 · Li 2020 · Ann Rheum Dis

Glucose-Metabolism Safety (Systematic Review)

Null / no benefit Meta-analysis supported

11 studies6 RCTs + 5 prospective
inconclusivemixed evidence

A systematic review of 11 human studies found mixed and inconclusive evidence on whether exogenous glucosamine affects glucose metabolism, concluding more studies are needed especially in people at high risk of impaired glucose homeostasis. In practice this means the early theoretical concern that glucosamine worsens insulin resistance has not been confirmed, but a diabetic-population caution is retained.

Reported effect: 11 studies (6 RCTs, 5 prospective); evidence on glucose metabolism mixed and inconclusive

“Clinical studies, including three using oral glucosamine, have provided mixed evidence about the effect of exogenous glucosamine on glucose metabolism in humans. Therefore, more studies are needed, particularly including subjects at high risk for impairments in glucose homeostasis, before a definite conclusion can be made.”

Source: PMID 21251987 · Dostrovsky 2011 · Osteoarthritis Cartilage

Dosage (research context · not a recommendation)

1500 mg/day glucosamine (single or 3 divided doses), often combined with 1200 mg/day chondroitin sulfate. Clinical onset is slow (4-8 weeks); structural-endpoint trials run 6-36 months. Strongest evidence is specifically for crystalline glucosamine SULFATE (pCGS) at 1500 mg/day; glucosamine HCl human data are weaker (the GAIT trial used HCl).

Regulatory Status · 4 Markets

US · FDA: Dietary-supplement ingredient under DSHEA (pre-1994 'old' ingredient, no NDI needed); glucosamine HCl is GRAS; USP-NF monographs exist for glucosamine sulfate, glucosamine HCl, and chondroitin sulfate sodium. Structure/function claims only — disease (OA 'treatment') claims prohibited; mandatory FDA disclaimer required. Undeclared crustacean allergen = Class I recall (FALCPA).
EU · EFSA: EFSA REJECTED all Article 13 joint-health claims for glucosamine (evidence deemed insufficient for causality given heterogeneity of sulfate vs HCl, dose, and population) — NO authorized EU health claim as a food supplement. Separately, crystalline glucosamine sulfate (pCGS, Dona/Viartril-S) is a PRESCRIPTION SYSADOA drug in several EU states (IT/ES/PT/IE/GR) and is ESCEO-recommended as OA Step-1; prescription-drug evidence must NOT be cited to support supplement claims. Crustacean allergen labeling mandatory (Reg 1169/2011).
CN · China: SAMR health-food raw material in the permitted-ingredient catalogue; approved function 'enhances bone mineral density' (100+ registrations). Not a novel food / not permitted in conventional foods.
BR · ANVISA: Permitted dietary-supplement ingredient (Suplemento Alimentar). RDC 243/2018 framework; IN 28/2018 positive list. Limits: glucosamine <=1500 mg/day, chondroitin sulfate <=1200 mg/day. Portuguese labeling required; crustacean allergen must be labeled 'Contém derivados de crustáceos'. (China SAMR: health-food ingredient, approved function 'enhances bone mineral density'; NOT permitted in conventional foods; also marketed separately as an Rx OA drug.)

Safety

Generally well tolerated; in long-term RCTs (up to 3 years) adverse-event rates are comparable to placebo, most commonly mild GI upset (nausea, bloating, diarrhea). CRUSTACEAN ALLERGEN — HARD red line: most glucosamine is shellfish-derived (shrimp/crab shell) and must be labeled as crustacean-sourced; shellfish-allergic individuals should avoid unless a fermentation/corn-derived "shellfish-free" source is documented (FDA treats an undeclared crustacean allergen as a Class I recall). Warfarin: case reports of increased INR — anticoagulant users should be monitored. Glucose metabolism: early theoretical concern that glucosamine raises blood glucose is not consistently confirmed clinically — a systematic review found mixed evidence, with possible glucose signals in subjects with impaired glucose tolerance (Dostrovsky 2011 SR PMID 21251987; see also Muniyappa 2006 PMID 17065354), so diabetic-population labeling caution is retained. No adequate safety data in pregnancy, lactation, or children <18 — not recommended for these groups.

Goals: joint-bone

Lifestyles: senior-60-plus

References

PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.

PMID 16495392 · Clegg 2006 · N Engl J Med — Knee Osteoarthritis Symptoms (Primary RCT)
PMID 35024906 · Meng 2023 · Arch Orthop Trauma Surg — Glucosamine + Chondroitin Combination (Meta-Analysis)
PMID 29018060 · Liu 2018 · Br J Sports Med — Glucosamine Monotherapy for OA Pain (Meta-Analysis)
PMID 38581640 · Rabade 2024 · Inflammopharmacology — Form-Specific Effects: Glucosamine Sulfate vs Combination (SR/MA)
PMID 18821708 · Sawitzke 2008 · Arthritis Rheum — Cartilage Structure / Joint-Space Width (GAIT Structural Arm)
PMID 25719429 · Navarro 2015 · PLoS One — Inflammatory-Marker (CRP) Modulation (RCT in Healthy Adults)
PMID 32253185 · Li 2020 · Ann Rheum Dis — All-Cause and Cardiovascular Mortality Association (Cohort — Observational)
PMID 21251987 · Dostrovsky 2011 · Osteoarthritis Cartilage — Glucose-Metabolism Safety (Systematic Review)

Frequently Asked Questions

1. Does the form of glucosamine matter — sulfate vs HCl?

Yes. A 2024 systematic review found that glucosamine sulfate significantly reduced tibiofemoral joint-space narrowing, while the glucosamine-plus-chondroitin combination showed neither a pain nor a function benefit in its analysis. The negative GAIT primary trial used glucosamine HCl. Across the literature, crystalline glucosamine sulfate carries the stronger signal, which is one reason results across studies disagree.

2. Can glucosamine slow cartilage loss or modify the disease?

In the GAIT structural sub-study (357 subjects / 581 knees), no treatment group including glucosamine showed a statistically significant difference in joint-space-width loss over 2 years versus placebo, and none reached the predefined threshold for a clinically important structural difference. So the cartilage-preservation hypothesis was not supported in that trial. A separate 2024 review did report glucosamine sulfate reducing joint-space narrowing, so structural findings are not consistent.

3. Does glucosamine affect inflammation or mortality?

In a small crossover RCT of healthy overweight adults (n=18), glucosamine plus chondroitin lowered serum CRP by 23% (P=0.048), with no change in IL-6 or other markers — a biomarker signal, not a clinical outcome. In the UK Biobank cohort (n=495,077), regular use was associated with lower all-cause mortality (HR 0.85) and cardiovascular mortality (HR 0.82). That association is observational only and is not evidence of a causal or longevity benefit.

4. Is glucosamine safe for people with diabetes or blood-sugar concerns?

A systematic review of 11 human studies (6 RCTs, 5 prospective) found mixed and inconclusive evidence on whether glucosamine affects glucose metabolism, calling for more research in people at high risk of impaired glucose homeostasis. The early theoretical concern that it worsens insulin resistance has not been confirmed in trials, though a precautionary note for diabetic populations is generally retained. This is evidence reporting, not personal medical guidance.

5. Why is there no authorized EU joint-health claim, and what is the allergen issue?

EFSA rejected all Article 13 joint-health claims for glucosamine, citing insufficient evidence for causality given heterogeneity in form (sulfate vs HCl), dose, and population — consistent with the mixed trial picture above. Note that crystalline glucosamine sulfate is separately a prescription drug in several EU states, and that drug evidence cannot be used to support supplement claims. Separately, most glucosamine is crustacean-derived (shrimp/crab shell), a hard allergen flag for shellfish-allergic individuals unless a documented shellfish-free source is used.

Last evidence review: 2026-06-13

← Evidence library